This session, moderated by Prof. Cortes and presented by Prof. Barrios and Prof. Del Mastro, focused on the mechanisms of action and clinical implications of CDK 4/6 inhibitors in hormone receptor-positive breast cancer.
Prof. Carlos Barrios focused on the mechanisms of action, clinical implications, and comparative effectiveness of CDK 4/6 inhibitors in treating hormone receptor-positive breast cancer.
1:22 - Mechanism of Action of CDK 4/6 Inhibitors: Prof. Barrios discusses the complex biology of hormone receptor-positive breast cancer and the role of CDK 4/6 inhibitors.
3:41 - Cell Cycle and Estrogen Signaling: He explains the interaction between estrogen signaling and the cell cycle, emphasizing the importance of cyclin D and CDK 4/6.
8:18 - Clinical Implications and Differences Among CDK 4/6 Inhibitors: He compares the three CDK 4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) and their clinical effects.
12:21 - Clinical Trials and Results: He reviews the outcomes of various clinical trials involving CDK 4/6 inhibitors in early breast cancer.
14:23 - Future Perspectives: He discusses the future development of combination therapies and the need for smarter trials to address sequencing strategies.
Prof. Lucia Del Mastro discussed the use of CDK 4/6 inhibitors, specifically abemaciclib and ribociclib, in early breast cancer treatment, highlighting their clinical benefits, differences in toxicity profiles, and guidelines for their use.
0:31 - Summary of CDK 4/6 Inhibitors: Lucia summarized the current role and open questions on the use of CDK 4/6 inhibitors in early breast cancer patients.
1:31 - Registration Trials: Overview of the registration trials for abemaciclib (MONARCHY trial) and ribociclib (Natalee trial), including their benefits in invasive disease-free survival.
7:18 - ESMO and ASCO Guidelines: Comparison of ESMO and ASCO guidelines on the use of CDK 4/6 inhibitors in early breast cancer patients.
9:12 - Risk Assessment: Analysis of patient outcomes based on risk criteria from the MONARCHY and Natalee trials.
11:00 - Conclusion: Final remarks on the benefits and considerations for using CDK 4/6 inhibitors in early breast cancer patients.
Panel Discussion
0:12 - Comparison of Three Drugs in Breast Cancer Treatment: Discussed the similarities and differences in progression-free survival and long-term outcomes of Palbociclib, Ribociclib, and Abemaciclib in metastatic and early breast cancer settings.
1:11 - Efficacy and Superiority of Abemaciclib and Ribociclib: Analysis of network meta-analysis and real-world studies showing the superiority of Abemaciclib and Ribociclib in breast cancer treatment.
2:23 - Patient Selection for CDK4/6 Inhibitors: Discussion on selecting the right patient population for CDK4/6 inhibitors and the impact of trial design on drug development.
3:28 - Inclusion Criteria for Monarch E and Natalee Trials: Analysis of the inclusion criteria for these trials and considerations for high-risk patients not included in the studies.
6:07 - Combination Therapies with CDK4/6 Inhibitors: Discussion on the potential of combining CDK4/6 inhibitors with AKT pathway inhibitors and the effectiveness of sequential treatments.
10:02 - Practical Considerations for Dose Adjustments: Addressing dose adjustments for Abemaciclib and Ribociclib in cases of significant side effects and the possibility of switching between these drugs.
13:00 - Re-challenging with CDK4/6 Inhibitors: Considerations for re-challenging patients with CDK4/6 inhibitors after disease progression and the potential benefits of switching between these inhibitors.